126 related articles for article (PubMed ID: 37427650)
1. Tumour sink effect on 68Ga-PMSA PET/CT: A case of diffuse metastatic disease of prostate cancer.
Usmani S; Riyami KA; Abubakar S; Jain A; Busaidi AA
J Pak Med Assoc; 2023 Jun; 73(6):1344-1345. PubMed ID: 37427650
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
4. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
5.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
6. Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
Vadi SK; Kumar R; Mittal BR; Parihar AS; Singh SK
Clin Nucl Med; 2018 Apr; 43(4):276-278. PubMed ID: 29465493
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls.
Keidar Z; Gill R; Goshen E; Israel O; Davidson T; Morgulis M; Pirmisashvili N; Ben-Haim S
Cancer Imaging; 2018 Nov; 18(1):39. PubMed ID: 30382889
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-PSMA PET/CT Images of Multiple Cutaneous Metastases in a Patient With Prostate Carcinoma: Complete Response to 177Lu-PSMA-617 Treatment.
Sivrikoz IA; Deveci H; Ak AM; Acer E
Clin Nucl Med; 2023 Nov; 48(11):950-952. PubMed ID: 37812519
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
10. Exceptional Response of Rare Plasmacytoid Variant Prostate Cancer Post 177Lu-PSMA Therapy Seen on 68Ga-PSMA PET/CT.
Maharaj M; Heslop L; Govender T; Korowlay N
Clin Nucl Med; 2023 Feb; 48(2):e69-e70. PubMed ID: 36607375
[TBL] [Abstract][Full Text] [Related]
11. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT.
Lawal I; Vorster M; Boshomane T; Ololade K; Ebenhan T; Sathekge M
Clin Nucl Med; 2015 Sep; 40(9):755-6. PubMed ID: 26053729
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
14. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
15. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
Zhao R; Li Y; Nie L; Qin K; Zhang H; Shi H
Medicine (Baltimore); 2021 Apr; 100(15):e25417. PubMed ID: 33847640
[TBL] [Abstract][Full Text] [Related]
16. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
18.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparisons of [
Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
